Dr. Vinod Kumar Gurjar

Employment

• School of Pharmacy Parul University Associate professor
  2019 - Present

Education

Education history is unavailable.

Projects & Funding

Projects & funding information is unavailable.

Publications (27)

• Recent Updates on Novel Quinazoline‐Hybrid Molecules Possessing EGFR‐Mediated Anticancer Activity
  ChemistrySelect 2026 DOI: 10.1002/slct.74007
  +Save
• Azoles (triazole and imidazole) scaffolds in anticancer drug design
  Nitrogen Heterocycles in Cancer Therapy 2025 DOI: 10.1016/b978-0-443-33106-0.00004-8
  +Save
• Effective Treatment and Control of Anti-Proliferative Diseases with Orange and Kumquat Seeds: Description, Chemistry and Uses
  Seeds: Anti-proliferative Storehouse for Bioactive Secondary Metabolites 2024 DOI: 10.1007/978-981-97-3014-8_20
  +Save
• Need of Carambola and Yunnan Pomegranate Seed in Controlling Proliferative Diseases
  Seeds: Anti-proliferative Storehouse for Bioactive Secondary Metabolites 2024 DOI: 10.1007/978-981-97-3014-8_19
  +Save
• Role of Moringa Seed and Its Secondary Metabolites Against Cancer: Chemistry, Morphology, and Mode of Action
  Seeds: Anti-proliferative Storehouse for Bioactive Secondary Metabolites 2024 DOI: 10.1007/978-981-97-3014-8_22
  +Save
• Green Analytical Chemistry: Sustainable Method Development and Validation Approaches
  Zenodo 2024 DOI: 10.5281/ZENODO.10968912
  +Save
• PROPERTIES AND ANALYTICAL METHOD FOR DETERMINATION FLOURO OF QUINOLONES: A REVIEW
  Zenodo 2024 DOI: 10.5281/ZENODO.10968894
  +Save
• Caspase-3: A promising target for anticancer agents
  Caspases as Molecular Targets for Cancer Therapy 2024 DOI: 10.1016/b978-0-443-15644-1.00005-5
  +Save
• Chapter 12 - Proviral integration site for Moloney murine leukemia virus-1 (PIM-1) kinase inhibitors
  Current Molecular Targets of Heterocyclic Compounds for Cancer Therapy 2024 DOI: https://doi.org/10.1016/B978-0-323-96121-9.00012-7
  +Save
• Chapter 13 - Rearranged during transfection (RET) inhibitors
  Current Molecular Targets of Heterocyclic Compounds for Cancer Therapy 2024 DOI: https://doi.org/10.1016/B978-0-323-96121-9.00013-9
  +Save